×

The RACGP website is undergoing scheduled maintenance on Tuesday, 5th December 2023 from 7:00 AM to 9:00 AM AEDT. During this time, the application will be unavailable. We apologise for any inconvenience caused.


Prescribing drugs of dependence in general practice

Part C2 - The role of opioids in pain management - Chapter 2

Pain – The basic concepts

Part C2 - The role of opioids in pain management
    6. Pain – The basic concepts
Download PDF

Last revised: 02 Jun 2020

The International Association for the Study of Pain (IASP) defines pain as ‘an unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage’.158

Acute pain is experienced from actual or threatened damage to tissue and is due to activation of nociceptors. Chronic pain describes persistent or recurrent pain (typically three months or more) and includes multiple pain conditions including CNCP (eg fibromyalgia, non-specific back pain, osteoarthritis, headache), chronic cancer pain and CPSP.123,159

The understanding of pain has broadened from a simple stimulus–response model (biomedical) to encompass the whole person. Each individual’s pain experience is affected by a complex combination of biomedical, psychological and social factors. The social and psychological factors are commonly the main determinants, especially of CNCP. To reflect this, Australian authorities have formally moved to a biopsychosocial framework. Note that the term ‘biopsychosocial’ is used in this guide without implying an order of importance.

The degree of pain and disability experienced in relation to similar physical injury varies. Similarly, there is individual variation in response to methods used to alleviate pain. Communication of the pain experience can be difficult. Patients are often frustrated and distressed by the limitations of language in expressing their pain experience.

When planning management and interventions for pain, these factors need to be considered. Additional insights and effectiveness of treatment can be gained by exploring and integrating patients’ wishes and their past experiences.

In clinical practice, we have traditionally classified pain based on time: acute or chronic. This has limitations, one of which is that it perpetuates the misconception that chronic pain is just ‘unhealed’ acute pain.160–162 Instead of classifying pain in terms of time, it is far more important to understand the underlying pathophysiology of pain.

The classification of pain based on pathophysiology is dynamic.123 A change to the definition of neuropathic pain occurred in 2011, and a third descriptor for pain is currently being debated.163

Nociceptive pain

Nociceptive pain arises from actual or threatened damage to non-neural tissue and is predominantly due to activation of nociceptors.158,164 Nociceptive pain guards against tissue injury (eg warns of potentially damaging stimuli such as heat) and supports healing and repair (eg increases pain to normally innocuous stimuli to aid protection/immobilisation of injured tissue). It requires a normally functioning somatosensory nervous system.163,165

Nociceptive pain can be further classified depending on the location of nociceptors. ‘Visceral’ pain results from stimulation (due to stretch, inflammation or ischaemia) of nociceptors within the viscera. Pain experienced by stimulation of nociceptors in the musculoskeletal system is sometimes referred to as ‘somatic’ pain.

Typically, nociceptive pain only lasts in the presence of continual noxious stimuli and disappears after resolution of the tissue injury. However, certain diseases may generate recurrent or ongoing noxious stimuli to produce chronic nociceptive pain (eg rheumatoid arthritis).163,165

Neuropathic pain

Neuropathic pain is caused by a lesion or disease of the somatosensory nervous system. It is not a diagnosis but a clinical description of the pain resulting from an injury or damage to either the peripheral or central nervous system by mechanical trauma, metabolic diseases, neurotoxic chemicals, infection, or tumour invasion.163,165 To satisfy the diagnostic criteria of neuropathic pain, the lesion or disease must be demonstrable through:

  • an appropriate history (eg episode of shingles within the past six months, limb amputation)
  • the presence of signs of neurological deficit
  • diagnostic interventions (eg imaging, neurophysiology)
  • confirmation of underlying cause (eg stroke, type 2 diabetes, multiple sclerosis).

Chronic neuropathic pain is not a single entity, but refers to a heterogeneous group of pain conditions. Nociceptive pain and neuropathic pain may occur together. For example, a study of patients with prolonged low back pain found that about 37% had a predominant neuropathic pain component.166

Unfortunately, current treatment of neuropathic pain is less than ideal, with fewer than 50% of patients experiencing satisfactory pain relief and tolerable side effects.167

Nociplastic pain

Patients initially experiencing nociceptive pain, such as osteoarthritis, may develop alterations in nociceptive processing manifested as altered descending pain inhibition168,169 accompanied by spread of hypersensitivity.170–172 Clinicians working in the field of pain have recognised the need for a word to describe pain that arises from altered nociception despite no clear evidence of:

  • actual or threatened tissue damage causing the activation of peripheral nociceptors (nociceptive pain)
  • disease or lesion of the somatosensory system causing the pain (neuropathic pain).

Nociplastic pain is described as pain caused by altered function of nociceptive pathways in the peripheral or central nervous system. These terms reflect the underlying pathophysiological change (sensitisation) in the nervous system.163

This classification describes the pain of conditions including fibromyalgia, CRPS, ‘non-specific’ chronic low back pain, and functional visceral pain disorders (eg irritable bowel syndrome, bladder pain syndrome, chronic abdominal pain, and chronic pelvic pain).

The assessment of pain using a biopsychosocial (or sociopsychobiomedical) framework takes into account the multiple factors (social, psychological, biological) that influence the pain experience. It completes a more complex understanding of the patient’s pain perspective as well as identifying other targets for management. Factors do not always neatly fit into one category; for example, depression may have physical and social aspects as well as being a psychological factor influencing pain. A comprehensive pain assessment includes a:

  • general assessment and pain-specific history (which explores the pain type, severity, functional impact, context, and the patient’s meaning of pain, expectations and fears)
  • physical examination (assessing for signs of tissue damage or disease that might indicate nociceptive and/or neuropathic and/or nociplastic mechanisms of pain)
  • psychological assessment (the pain experience is affected by mood, stress, coping skills, fear avoidance, and catastrophising).

This will inform the selection of treatment options most likely to be effective. The assessment may need to be repeated reasonably frequently, particularly while establishing a diagnosis and appropriate pain management.

The following descriptions provide more detail on the pain assessment including links to useful assessment templates and questionnaires.

General assessment and pain history

The standard medical assessment is as important in pain as it is in any other medical or psychological condition. Particularly with pain, history taking will explore multiple aspects such as any injury, details about the pain experience and impact, and attempted treatments (Table 1). The purpose of the assessment is to establish a possible physical mechanism of pain (whether it is nociceptive, neuropathic, nociplastic or a combination of aetiologies) and if there are underlying conditions or psychosocial issues.

When appropriate, a pain screening questionnaire may assist in the understanding of the patient’s pain experience. These include the Brief pain inventory, McGill pain questionnaire, DN4 neuropathic pain questionnaire and the Örebro musculoskeletal pain screening questionnaire.

Social assessment

Social assessment identifies factors in the patient’s environment that influence the pain experience. These include family and other relationships, work, life events, housing, sleep, activity and nutrition. Pain may be influenced by culture (eg seen as a way to strengthen the body, purify the soul or deepen the spirit with the idea of ‘no pain no gain’).

Pain influences interactions with others, occupational performance and self-care. Pain can be socially isolating, which can contribute to the pain–depression cycle. The patient should be questioned about the impact of pain on function (social and physical) and overall quality of life (Table 2). Specific questions might include the following:173 • Social and recreational functioning

  • How often do you participate in pleasurable activities, such as hobbies, going out to movies or concerts, socialising with friends, and travel?
  • Over the past week, how often has pain interfered with these activities?
  • Mood, affect, and anxiety (for more information, refer to 2.3.3 Psychological assessment) – Has pain interfered with your energy, mood, or personality?
    • Are you readily tearful?
  • Relationships
    • Has pain affected relationships with family members, significant others, friends or colleagues? • Occupation
    • Has the pain required that you modify your work responsibilities and/or hours?
    • When was the last time you worked, and (if applicable) why have you stopped working? • Sleep
    • Does pain interfere with your sleep? How often over the past week?
  • Exercise
    • How often do you do some sort of exercise?
    • Over the past week, how often has pain interfered with your ability to exercise?

To assess the true impact of pain on the patient’s life, it helps to have familiarity with the patient and/or obtain input from their family, friends and support systems.

Occasionally, pain is used to gain sympathy, protection, benefits or medico-legal compensation.

Physical examination

A physical examination, including a thorough musculoskeletal examination, is particularly important in most of the chronic pain conditions and a relevant neurological examination is particularly important for neuropathic pain. A physical examination might include:

  • assessing for signs of tissue damage/injury or disease that might indicate nociceptive and/or neuropathic mechanisms of pain (eg tissue deformity and cardinal signs of inflammation, or signs of neural disease or damage)
  • careful evaluation for sources of referred pain (including viscera)
  • looking for evidence of hypervigilance or guarding with particular movements. Compensatory postures and movements are important to analyse, as they might be placing extra load on sensitive tissues and addressing these early can avoid development of secondary issues
  • looking for evidence of allodynia, hypoalgesia and hyperalgesia.

At the end of the examination, the GP should aim to establish a provisional diagnosis for the pain and the biomedical mechanism involved, as well as analysis regarding the disability level of the patient.

Psychological assessment

Psychological assessment explores the patient’s mood state, beliefs, thinking styles, coping skills, behaviours and responses that may contribute to the experience of pain, obstacles to recovery and treatment outcome.174 Psychological factors that contribute to the experience and impact of pain can be amenable to change175 and thus influence outcomes for the individual.176 There are screening tools for many of these factors.

Experience of both acute and chronic pain is commonly accompanied and influenced by mood and anxiety disorders.174 For example, anxiety is one of the most significant predictive factors for the severity of postoperative pain177 and there is a consistent association between CPSP and depression.125

Relevant beliefs include understanding of diagnosis and prognosis, and expectations about treatment, including willingness to be an active participant. Many people have a fear of pain, which contributes to the development of avoidance responses and can ultimately lead to disability. Thinking styles that are overly negative, ruminative and helpless (eg catastrophic thinking) are associated with more severe acute pain as well as persistent pain.178

Measurement of pain and functional impact

There are several pain scoring systems. Verbal numerical rating scales are often preferred because they are simpler to administer and give consistent results.179

The PEG scale may be useful in the general practice setting, particularly when assessing chronic musculoskeletal pain.109 Scores (out of 30) give a reference point for the patient’s overall wellbeing and can be used to compare the same patient seen at different times or by different practitioners.109

As so many factors influence the experience (and communication) of pain, it is not surprising that pain scores do not provide information about which patients are likely to respond to opioids.180

Box 7.

Pain diary

NPS MedicineWise has a pain diary that patients can access and download from their website.

Risk assessment

Opioids are often useful analgesics, but care needs to be taken when prescribing these drugs to limit the risks, including inappropriate use and diversion. Clinically, problematic opioid usage is more likely when used in:

  • younger patients – substance use issues generally commence before 35 years of age
  • patients without a definite patho-anatomic diagnosis
  • patients with active substance use problems or who are in contact with patients with such problems
  • patients with active psychiatric problems
  • patients who use benzodiazepines – concomitant use of opioids substantially increases the risks of side effects, particularly cognitive impairment, sedation and respiratory depression.181

Comprehensive assessment addresses the risk of opioid misuse.182,183 While screening for opioid risk has been recommended, at this point evidence of effectiveness is lacking. Additionally, treatment agreements and urine testing are also recommended but have not been shown to reduce overall rates of opioid prescribing, misuse, or overdose.5,103

Patients with a history of SUD are at higher risk of harms. A check of state-based prescription monitoring systems is advocated. Those patients with a history of SUD should probably not be offered opioids in a general practice setting, but, rather, if pain control cannot be gained by other means, should be offered referral to specialist services.

A UDS may reveal evidence of substances of which the practitioner is not aware. Not all substances are routinely tested for (eg oxycodone testing needs to be specifically requested). If such drugs are found, whether illicit or legal, the patient should be referred for specialist assessment and management. Contacting your local pathology provider may be necessary.

  1. Cohen M, Quintner J, Buchanan D. Is chronic pain a disease? Pain Med 2013;14(9):1284–88.
  2. Upshur CC, Luckmann RS, Savageau JA. Primary care provider concerns about management of chronic pain in community clinic populations. J Gen Intern Med 2006;21(6):652–55.
  3. Henderson JV, Harrison CM, Britt HC, Bayram CF, Miller GC. Prevalence, causes, severity, impact, and management of chronic pain in Australian general practice patients. Pain Med 2013;14(9):1346–61.
  4. O’Rorke JE, Chen I, Genao I, Panda M, Cykert S. Physicians’ comfort in caring for patients with chronic nonmalignant pain. Am J Med Sci 2007;333(2):93–100.
  5. Australian and New Zealand College of Anaesthetists. Recommendations regarding the use of opioid analgesics in patients with chronic non-cancer pain. Melbourne: ANZCA, 2015 PM1-2010.pdf [Accessed 19 July 2017].
  6. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: An emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336(7650):924–26. [Accessed 19 July 2017].
  7. Schug S, Palmer G, Scott D, et al. Acute pain management: Scientific evidence. 4th edn. Melbourne: ANZCA, 2015 Documents/APMSE4_2015_Final [Accessed 19 July 2017].
  8. Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain – United States, 2016. JAMA 2016;315(15):1624–45. [Accessed 19 July 2017].
  9. Saragiotto BT, Machado GC, Ferreira ML, Pinheiro MB, Abdel Shaheed C, Maher CG. Paracetamol for low back pain. Cochrane Database Syst Rev 2016(6):CD012230. [Accessed 19 July 2017].
  10. Williams CM, Maher CG, Latimer J, et al. Efficacy of paracetamol for acute low-back pain: A double-blind, randomised controlled trial. Lancet 2014;384(9954):1586–96. [Accessed 19 July 2017].
  11. Moore RA, Derry S, Aldington D, Wiffen PJ. Single dose oral analgesics for acute postoperative pain in adults – An overview of Cochrane reviews. Cochrane Database Syst Rev 2015(9):CD008659. [Accessed 19 July 2017].
  12. Moore RA, Derry S, Wiffen PJ, Straube S, Aldington DJ. Overview review: Comparative efficacy of oral ibuprofen and paracetamol (acetaminophen) across acute and chronic pain conditions. Eur J Pain 2015;19(9):1213–23. [Accessed 19 July 2017].
  13. Moore RA, Derry S, Aldington D, Wiffen PJ. Adverse events associated with single dose oral analgesics for acute postoperative pain in adults – An overview of Cochrane reviews. Cochrane Database Syst Rev 2015(10):CD011407. [Accessed 19 July 2017].
  14. Ong CK, Seymour RA, Lirk P, Merry AF. Combining paracetamol (acetaminophen) with nonsteroidal antiinflammatory drugs: A qualitative systematic review of analgesic efficacy for acute postoperative pain. Anesth Analg 2010;110(4):1170–79. [Accessed 19 July 2017].
  15. Bailey E, Worthington HV, van Wijk A, Yates JM, Coulthard P, Afzal Z. Ibuprofen and/or paracetamol (acetaminophen) for pain relief after surgical removal of lower wisdom teeth. Cochrane Database Syst Rev 2013;12:CD004624. [Accessed 19 July 2017].
  16. Shaheed CA, Maher CG, McLachlan AJ. Investigating the efficacy and safety of over-the-counter codeine containing combination analgesics for pain and codeine based antitussives. Canberra: Therapeutic Goods Association, 2016 [Accessed 19 July 2017].
  17. Blondell RD, Azadfard M, Wisniewski AM. Pharmacologic therapy for acute pain. Am Fam Physician 2013;87(11):766–72. [Accessed 19 July 2017].
  18. Bendtsen L, Evers S, Linde M, et al. EFNS guideline on the treatment of tension-type headache – Report of an EFNS task force. Eur J Neurol 2010;17(11):1318–25. [Accessed 19 July 2017].
  19. Thorson D, Biewen P, Bonte B, et al. Acute pain assessment and opioid prescribing protocol. Bloomington, MN: Institute for Clinical Systems Improvement, 2014 Opioids.pdf [Accessed 1 September 2017].
  20. Australian and New Zealand College of Anaesthetists. Guidelines on acute pain management. Melbourne: ANZCA, 2013 Documents/ps41-2013-guidelines-on-acute-painmanagement [Accessed 19 July 2017].
  21. Traeger AC, Hubscher M, Henschke N, Moseley GL, Lee H, McAuley JH. Effect of primary care-based education on reassurance in patients with acute low back pain: Systematic review and meta-analysis. JAMA Intern Med 2015;175(5):733–43. [Accessed 19 July 2017].
  22. Qaseem A, Wilt TJ, McLean RM, Forciea MA, Clinical Guidelines Committee of the American College of Physicians. Noninvasive treatments for acute, subacute, and chronic low back pain: A clinical practice guideline from the American College of Physicians. Ann Intern Med 2017;166(7):514–30. [Accessed 19 July 2017].
  23. Chung JW, Zeng Y, Wong TK. Drug therapy for the treatment of chronic nonspecific low back pain: Systematic review and meta-analysis. Pain Physician 2013;16(6):E685–704. [Accessed 19 July 2017].
  24. van den Bekerom MP, Sjer A, Somford MP, Bulstra GH, Struijs PA, Kerkhoffs GM. Non-steroidal anti-inflammatory drugs (NSAIDs) for treating acute ankle sprains in adults: Benefits outweigh adverse events. Knee Surg Sports Traumatol Arthrosc 2015;23(8):2390–99. [Accessed 19 July 2017].
  25. Massey T, Derry S, Moore RA, McQuay HJ. Topical NSAIDs for acute pain in adults. Cochrane Database Syst Rev 2010(6):CD007402. [Accessed 19 July 2017].
  26. Predel HG, Giannetti B, Seigfried B, Novellini R, Menke G. A randomized, double-blind, placebo-controlled multicentre study to evaluate the efficacy and safety of diclofenac 4% [Accessed 19 July 2017].
  27. spray gel in the treatment of acute uncomplicated ankle sprain. J Int Med Res 2013;41(4):1187–202. [Accessed 19 July 2017].
  28. Predel HG, Hamelsky S, Gold M, Giannetti B. Efficacy and safety of diclofenac diethylamine 2.32% gel in acute ankle sprain. Med Sci Sports Exerc 2012;44(9):1629–36. [Accessed 19 July 2017].
  29. Serinken M, Eken C, Turkcuer I, Elicabuk H, Uyanik E, Schultz CH. Intravenous paracetamol versus morphine for renal colic in the emergency department: A randomised double-blind controlled trial. Emerg Med J 2012;29(11):902–95. [Accessed 19 July 2017].
  30. Holdgate A, Pollock T. Nonsteroidal anti-inflammatory drugs (NSAIDs) versus opioids for acute renal colic. Cochrane Database Syst Rev 2005(2):CD004137. [Accessed 19 July 2017].
  31. Afshar K, Jafari S, Marks AJ, Eftekhari A, MacNeily AE. Nonsteroidal anti-inflammatory drugs (NSAIDs) and nonopioids for acute renal colic. Cochrane Database Syst Rev 2015(6):CD006027. [Accessed 19 July 2017].
  32. Turk C, Petrik A, Sarica K, et al. EAU guidelines on diagnosis and conservative management of urolithiasis. Eur Urol 2016;69(3):468–74. [Accessed 19 July 2017].
  33. Sin B, Koop K, Liu M, Yeh JY, Thandi P. Intravenous acetaminophen for renal colic in the emergency department: Where do we stand? Am J Ther 2017;24(1):e12–e19. [Accessed 19 July 2017].
  34. Campschroer T, Zhu Y, Duijvesz D, Grobbee DE, Lock MT. Alpha-blockers as medical expulsive therapy for ureteral stones. Cochrane Database Syst Rev 2014;4:CD008509. [Accessed 19 July 2017].
  35. Colli A, Conte D, Valle SD, Sciola V, Fraquelli M. Metaanalysis: Nonsteroidal anti-inflammatory drugs in biliary colic. Aliment Pharmacol Ther 2012;35(12):1370–78. [Accessed 19 July 2017].
  36. National Institute for Health and Clinical Excellence. Gallstone disease: Diagnosis and initial management. NICE guidelines CG188. London: NICE, 2014. Available at www. [Accessed 21 July 2017].
  37. Zakko SF. Uncomplicated gallstone disease in adults. UpToDate, 2016 uncomplicated-gallstone-disease-in-adults?topicKey=GAST %2F654&elapsedTimeMs=5&source=machineLearning&se archTerm=biliary+colic&selectedTitle=1%7E150&view=print &displayedView=full&anchor=H25 [Accessed 21 July 2017].
  38. Moore PA, Hersh EV. Combining ibuprofen and acetaminophen for acute pain management after thirdmolar extractions: Translating clinical research to dental practice. J Am Dent Assoc 2013;144(8):898–908. [Accessed 21 July 2017].
  39. Marjoribanks J, Proctor M, Farquhar C, Derks RS. [Accessed 21 July 2017].
  40. Nonsteroidal anti-inflammatory drugs for dysmenorrhoea. Cochrane Database Syst Rev 2010(1):CD001751. [Accessed 21 July 2017].
  41. Cunningham A, Breuer J, Dwyer D, et al. The prevention and management of herpes zoster. Med J Aust 2008;188(3):171–76. [Accessed 21 July 2017].
  42. Dworkin RH, Johnson RW, Breuer J, et al. [Accessed 21 July 2017].
  43. Recommendations for the management of herpes zoster. Clin Infect Dis 2007;44(Suppl 1):S1–26. [Accessed 21 July 2017].
  44. Dwyer DE, Cunningham AL. 10: Herpes simplex and varicella-zoster virus infections. Med J Aust 2002;177(5):267–73. [Accessed 21 July 2017].
  45. Berry JD, Petersen KL. A single dose of gabapentin reduces acute pain and allodynia in patients with herpes zoster. Neurology 2005;65(3):444–47. [Accessed 21 July 2017].
  46. Jensen-Dahm C, Rowbotham MC, Reda H, Petersen KL. [Accessed 21 July 2017].
  47. Effect of a single dose of pregabalin on herpes zoster pain. Trials 2011;12:55. [Accessed 21 July 2017].
  48. Lin PL, Fan SZ, Huang CH, et al. Analgesic effect of lidocaine patch 5% in the treatment of acute herpes zoster: A double-blind and vehicle-controlled study. Reg Anesth Pain Med 2008;33(4):320–25. [Accessed 21 July 2017].
  49. Chen N, Li Q, Yang J, Zhou M, Zhou D, He L. Antiviral treatment for preventing postherpetic neuralgia. Cochrane Database Syst Rev 2014(2):CD006866. [Accessed 21 July 2017].
  50. Chen N, Yang M, He L, Zhang D, Zhou M, Zhu C. [Accessed 21 July 2017].
  51. Corticosteroids for preventing postherpetic neuralgia. Cochrane Database Syst Rev 2010(12):CD005582. [Accessed 21 July 2017].
  52. Saarto T, Wiffen PJ. Antidepressants for neuropathic pain: A Cochrane review. J Neurol Neurosurg Psychiatry 2010;81(12):1372–73. [Accessed 21 July 2017].
  53. Moore RA, Derry S, Wiffen PJ, Straube S, Bendtsen L. Evidence for efficacy of acute treatment of episodic tensiontype headache: Methodological critique of randomised trials for oral treatments. Pain 2014;155(11):2220–28. [Accessed 21 July 2017].
  54. Chaibi A, Russell MB. Manual therapies for cervicogenic headache: A systematic review. J Headache Pain 2012;13(5):351–59. [Accessed 21 July 2017].
  55. Luedtke K, Allers A, Schulte LH, May A. Efficacy of interventions used by physiotherapists for patients with headache and migraine-systematic review and metaanalysis. Cephalalgia 2016;36(5):474–92. [Accessed 21 July 2017].
  56. Derry S, Moore RA. Paracetamol (acetaminophen) with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst Rev 2013;4:CD008040. [Accessed 21 July 2017].
  57. Kirthi V, Derry S, Moore RA. Aspirin with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst Rev 2013;4:CD008041. [Accessed 21 July 2017].
  58. Rabbie R, Derry S, Moore RA. Ibuprofen with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst Rev 2013;4:CD008039. [Accessed 21 July 2017].
  59. Derry S, Rabbie R, Moore RA. Diclofenac with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst Rev 2013;4:CD008783. [Accessed 21 July 2017].
  60. Colman I, Brown MD, Innes GD, Grafstein E, Roberts TE, Rowe BH. Parenteral metoclopramide for acute migraine: Meta-analysis of randomised controlled trials. BMJ 2004;329(7479):1369–73. [Accessed 21 July 2017].
  61. Friedman BW, Esses D, Solorzano C, et al. A randomized controlled trial of prochlorperazine versus metoclopramide for treatment of acute migraine. Ann Emerg Med 2008;52(4):399–406. [Accessed 21 July 2017].
  62. Coppola M, Yealy DM, Leibold RA. Randomized, placebo-controlled evaluation of prochlorperazine versus metoclopramide for emergency department treatment of migraine headache. Ann Emerg Med 1995;26(5):541–46. [Accessed 21 July 2017].
  63. Taggart E, Doran S, Kokotillo A, Campbell S, Villa-Roel C, Rowe BH. Ketorolac in the treatment of acute migraine: A systematic review. Headache 2013;53(2):277–87. [Accessed 21 July 2017].
  64. Thorlund K, Mills EJ, Wu P, et al. Comparative efficacy of triptans for the abortive treatment of migraine: A multiple treatment comparison meta-analysis. Cephalalgia 2014;34(4):258-67. [Accessed 21 July 2017].
  65. Tepper SJ. Opioids should not be used in migraine. Headache 2012;52(Suppl 1):30–34. [Accessed 21 July 2017].
  66. Buse DC, Pearlman SH, Reed ML, Serrano D, Ng-Mak DS, Lipton RB. Opioid use and dependence among persons with migraine: Results of the AMPP study. Headache 2012;52(1):18–36. [Accessed 21 July 2017].
  67. Finocchi C, Viani E. Opioids can be useful in the treatment of headache. Neurol Sci 2013;34(Suppl 1):S119–24. [Accessed 21 July 2017].
  68. Broner SW, Sun-Edelstein C, Lay CL. Cluster headache in women. Curr Pain Headache Rep 2007;11(2):127–30. [Accessed 21 July 2017].
  69. Finkel AG. Epidemiology of cluster headache. Curr Pain Headache Rep 2003;7(2):144–49. [Accessed 21 July 2017].
  70. Fischera M, Marziniak M, Gralow I, Evers S. The incidence and prevalence of cluster headache: A meta-analysis of population-based studies. Cephalalgia 2008;28(6):614–18. [Accessed 21 July 2017].
  71. Bennett MH, French C, Schnabel A, Wasiak J, Kranke P. Normobaric and hyperbaric oxygen therapy for migraine and cluster headache. Cochrane Database Syst Rev 2008(3):CD005219. [Accessed 21 July 2017].
  72. Cohen AS, Burns B, Goadsby PJ. High-flow oxygen for treatment of cluster headache: A randomized trial. JAMA 2009;302(22):2451–57. [Accessed 21 July 2017].
  73. Robbins MS, Starling AJ, Pringsheim TM, Becker WJ, [Accessed 21 July 2017].
  74. Schwedt TJ. Treatment of cluster headache: American Headache Society evidence-based guidelines. Headache 2016;56(7):1093–106. [Accessed 21 July 2017].
  75. Bennett MH, French C, Schnabel A, Wasiak J, Kranke P, Weibel S. Normobaric and hyperbaric oxygen therapy for the treatment and prevention of migraine and cluster headache. Cochrane Database Syst Rev 2015(12):CD005219. [Accessed 21 July 2017].
  76. Law S, Derry S, Moore RA. Triptans for acute cluster headache. Cochrane Database Syst Rev 2013;7:CD008042. [Accessed 21 July 2017].
  77. Francis GJ, Becker WJ, Pringsheim TM. Acute and preventive pharmacologic treatment of cluster headache. Neurology 2010;75(5):463–73. [Accessed 21 July 2017].
  78. van der Meer HA, Speksnijder CM, Engelbert R, [Accessed 21 July 2017].
  79. Lobbezoo F, Nijhuis-van der Sanden MW, Visscher CM. The association between headaches and temporomandibular disorders is confounded by bruxism and somatic complaints. Clin J Pain 2016. doi: 10.1097/ AJP.0000000000000470. [Accessed 21 July 2017].
  80. Costa YM, Conti PC, de Faria FA, Bonjardim LR. [Accessed 21 July 2017].
  81. Temporomandibular disorders and painful comorbidities: Clinical association and underlying mechanisms. Oral Surg Oral Med Oral Pathol Oral Radiol 2017;123(3):288–97. [Accessed 21 July 2017].
  82. Schiffman E, Ohrbach R, List T, et al. Diagnostic criteria for headache attributed to temporomandibular disorders. Cephalalgia 2012;32(9):683–92. [Accessed 21 July 2017].
  83. Mujakperuo HR, Watson M, Morrison R, Macfarlane TV. [Accessed 21 July 2017].
  84. Pharmacological interventions for pain in patients with temporomandibular disorders. Cochrane Database Syst Rev 2010(10):CD004715. [Accessed 21 July 2017].
  85. Ta LE, Dionne RA. Treatment of painful temporomandibular joints with a cyclooxygenase-2 inhibitor: A randomized placebo-controlled comparison of celecoxib to naproxen. Pain 2004;111(1-2):13–21. [Accessed 21 July 2017].
  86. Kelley JM, Kraft-Todd G, Schapira L, Kossowsky J, Riess H. The influence of the patient-clinician relationship on healthcare outcomes: A systematic review and metaanalysis of randomized controlled trials. PLoS One 2014;9(4):e94207. [Accessed 21 July 2017].
  87. National Opioid Use Guideline Group. Canadian guideline for safe and effective use of opioids for chronic non-cancer pain. Part B: Recommendations for practice. Ontario: [Accessed 21 July 2017].
  88. NOUGG, 2010. Available at http://nationalpaincentre. [Accessed 21 July 2017].
  89. Klinger R, Colloca L, Bingel U, Flor H. Placebo analgesia: Clinical applications. Pain 2014;155(6):1055–58. [Accessed 21 July 2017].
  90. Miller FG, Kaptchuk TJ. The power of context: Reconceptualizing the placebo effect. J R Soc Med 2008;101(5):222–25. [Accessed 21 July 2017].
  91. Lee C, Crawford C, Swann S, Active Self-Care Therapies for Pain Working Group. Multimodal, integrative therapies for the self-management of chronic pain symptoms. Pain Med 2014;15(Suppl 1):S76–85. [Accessed 21 July 2017].
  92. Hayden JA, van Tulder MW, Malmivaara A, Koes BW. Exercise therapy for treatment of non-specific low back pain. Cochrane Database Syst Rev 2005(3):CD000335. [Accessed 21 July 2017].
  93. Fransen M, McConnell S, Harmer AR, Van der Esch M, Simic M, Bennell KL. Exercise for osteoarthritis of the knee: A Cochrane systematic review. Br J Sports Med 2015;49(24):1554–57. [Accessed 21 July 2017].
  94. Fransen M, McConnell S, Hernandez-Molina G, [Accessed 21 July 2017].
  95. Reichenbach S. Exercise for osteoarthritis of the hip. Cochrane Database Syst Rev 2014;4:CD007912. [Accessed 21 July 2017].
  96. Busch AJ, Barber KA, Overend TJ, Peloso PM, Schachter CL. Exercise for treating fibromyalgia syndrome. Cochrane Database Syst Rev 2007(4):CD003786. [Accessed 21 July 2017].
  97. Scottish Intercollegiate Guidelines Network. Management of chronic pain (SIGN 136). Edinburgh: SIGN, 2013 [Accessed 1 September 2017].
  98. Williams AC, Eccleston C, Morley S. Psychological therapies for the management of chronic pain (excluding headache) in adults. Cochrane Database Syst Rev 2012;11:CD007407. [Accessed 1 September 2017].
  99. Eccleston C, Hearn L, Williams AC. Psychological therapies for the management of chronic neuropathic pain in adults. Cochrane Database Syst Rev 2015;10:CD011259. [Accessed 1 September 2017].
  100. Hooten W, Timming R, Belgrade M, et al. Assessment and management of chronic pain. Bloomington, MN: Institute for Clinical Systems Improvement, 2013 c26a36d83686607ad89ee835daa3c9db3f4c.pdf [Accessed 1 September 2017].
  101. Kahan M, Mailis-Gagnon A, Wilson L, Srivastava A, National [Accessed 1 September 2017].
  102. Opioid Use Guideline Group. Canadian guideline for safe and effective use of opioids for chronic noncancer pain: Clinical summary for family physicians. Part 1: General population. Can Fam Physician 2011;57(11):1257–66, e407-18. [Accessed 1 September 2017].
  103. The Royal Australasian College of Physicians. Prescription opioid policy: Improving management of chronic nonmalignant pain and prevention of problems associated with prescription opioid use. Sydney: RACP, 2009. [Accessed 1 September 2017].
  104. Manchikanti L, Abdi S, Atluri S, et al. American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: Part 2: Guidance. Pain Physician 2012;15(3 Suppl):S67–116. [Accessed 1 September 2017].
  105. National Center for Injury Prevention and Control. Common elements in guidelines for prescribing opioids for chronic pain. NCIPC, 2014 drugoverdose/pdf/common_elements_in_guidelines_for_ prescribing_opioids-a.pdf [Accessed 21 July 2017].
  106. Moulin D, Boulanger A, Clark AJ, et al. Pharmacological management of chronic neuropathic pain: Revised consensus statement from the Canadian Pain Society. Pain Res Manag 2014;19(6):328–35. [Accessed 21 July 2017].
  107. Whiting PF, Wolff RF, Deshpande S, et al. Cannabinoids for medical use: A systematic review and meta-analysis. JAMA. 2015;313(24):2456-73. [Accessed 21 July 2017].
  108. Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain in adults: A systematic review and meta-analysis. Lancet Neurol 2015;14(2):162–73. [Accessed 21 July 2017].
  109. Australian and New Zealand College of Anaesthetists. Statement on ‘medicinal cannabis’ with particular reference to its use in the management of patients with chronic noncancer pain (PM10). Melbourne: ANZCA, 2015 [Accessed 21 July 2017].
  110. Stacey BR, Barrett JA, Whalen E, Phillips KF, Rowbotham MC. Pregabalin for postherpetic neuralgia: Placebocontrolled trial of fixed and flexible dosing regimens on allodynia and time to onset of pain relief. J Pain 2008;9(11):1006–17. [Accessed 21 July 2017].
  111. Wang F, Ruberg SJ, Gaynor PJ, Heinloth AN, Arnold LM. Early improvement in pain predicts pain response at endpoint in patients with fibromyalgia. J Pain 2011;12(10):1088–94. [Accessed 21 July 2017].
  112. Therapeutics Initiative. Benefits and harms of drugs for ‘neuropathic’ pain. Vancouver: University of British Columbia, 2015 [Accessed 21 July 2017].
  113. Hughes MA, Biggs JJ, Theise MS, Graziano K, Robbins RB, Effiong AC. Recommended opioid prescribing practices for use in chronic non-malignant pain: A systematic review of treatment guidelines. J Manag Care Med 2011;14(3):52. [Accessed 21 July 2017].
  114. National Opioid Use Guideline Group. Canadian guideline for safe and effective use of opioids for chronic non-cancer pain. Ontario: NOUGG, 2010. Available at http://nationalpaincentre. [Accessed 21 July 2017].
  115. Deyo RA, Von Korff M, Duhrkoop D. Opioids for low back pain. BMJ 2015;350:g6380. [Accessed 21 July 2017].
  116. Chou R, Fanciullo GJ, Fine PG, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain 2009;10(2):113–30. [Accessed 21 July 2017].
  117. Fagan MJ, Chen JT, Diaz JA, Reinert SE, Stein MD. Do internal medicine residents find pain medication agreements useful? Clin J Pain 2008;24(1):35–38. [Accessed 21 July 2017].
  118. Bazazi AR, Zaller ND, Fu JJ, Rich JD. Preventing opiate overdose deaths: Examining objections to takehome naloxone. J Health Care Poor Underserved 2010;21(4):1108–13. [Accessed 21 July 2017].
  119. McDonald R, Strang J. Are take-home naloxone programmes effective? Systematic review utilizing application of the Bradford Hill criteria. Addiction 2016;111(7):1177–87. [Accessed 21 July 2017].
  120. Strang J, McDonald R, Alqurshi A, Royall P, Taylor D, Forbes B. Naloxone without the needle – Systematic review of candidate routes for non-injectable naloxone for opioid overdose reversal. Drug Alcohol Depend 2016;163:16–23. [Accessed 21 July 2017].
  121. Krebs EE, Lorenz KA, Bair MJ, et al. Development and initial validation of the PEG, a three-item scale assessing pain intensity and interference. J Gen Intern Med 2009;24(6):733–38. [Accessed 21 July 2017].
  122. Boudreau D, Von Korff M, Rutter CM, et al. Trends in long-term opioid therapy for chronic non-cancer pain. Pharmacoepidemiol Drug Saf 2009;18(12):1166–75. [Accessed 21 July 2017].
  123. Smith HS, Peppin JF. Toward a systematic approach to opioid rotation. J Pain Res 2014;7:589–608. [Accessed 21 July 2017].
  124. The British Pain Society. Opioids for persistent pain: Good practice. London: The British Pain Society, 2010. [Accessed 21 July 2017].
  125. Becker WC, Fraenkel L, Edelman EJ, et al. Instruments to assess patient-reported safety, efficacy, or misuse of current opioid therapy for chronic pain: A systematic review. Pain 2013;154(6):905–16. [Accessed 21 July 2017].
  126. Gourlay DL, Heit HA, Almahrezi A. Universal precautions in pain medicine: A rational approach to the treatment of chronic pain. Pain Med 2005;6(2):107–12. [Accessed 21 July 2017].
  127. Jammal W, Gown G. Opioid prescribing pitfalls: Medicolegal and regulatory issues. Aust Prescr 2015;38:198–203. [Accessed 21 July 2017].
  128. Noble M, Treadwell JR, Tregear SJ, et al. Long-term opioid management for chronic noncancer pain. Cochrane Database Syst Rev 2010(1):CD006605. [Accessed 21 July 2017].
  129. Häuser W, Bock F, Engeser P, Tölle T, Willweber-Strumpf A, Petzke F. Long-term opioid use in non-cancer pain. Dtsch Ärztebl Int 2014;111(43):732–40. [Accessed 21 July 2017].
  130. Tawfic Q, Kumar K, Pirani Z, Armstrong K. Prevention of chronic post-surgical pain: The importance of early identification of risk factors. J Anesth 2017;31(3):424–31. [Accessed 21 July 2017].
  131. Wylde V, Hewlett S, Learmonth ID, Dieppe P. Persistent pain after joint replacement: Prevalence, sensory qualities, and postoperative determinants. Pain 2011;152(3):566–72. [Accessed 21 July 2017].
  132. Chan MT, Wan AC, Gin T, Leslie K, Myles PS. Chronic postsurgical pain after nitrous oxide anesthesia. Pain 2011;152(11):2514–20. [Accessed 21 July 2017].
  133. Macrae WA. Chronic post-surgical pain: 10 years on. Br J Anaesth 2008;101(1):77–86. [Accessed 21 July 2017].
  134. Kehlet H, Jensen TS, Woolf CJ. Persistent postsurgical pain: Risk factors and prevention. Lancet 2006;367(9522):1618–25. [Accessed 21 July 2017].
  135. Treede RD, Rief W, Barke A, et al. A classification of chronic pain for ICD-11. Pain 2015;156(6):1003–7. [Accessed 21 July 2017].
  136. Theunissen M, Peters ML, Bruce J, Gramke HF, Marcus MA. Preoperative anxiety and catastrophizing: A systematic review and meta-analysis of the association with chronic postsurgical pain. Clin J Pain 2012;28(9):819–41. [Accessed 21 July 2017].
  137. Hinrichs-Rocker A, Schulz K, Jarvinen I, Lefering R, Simanski C, Neugebauer EA. Psychosocial predictors and correlates for chronic post-surgical pain (CPSP) – A systematic review. Eur J Pain 2009;13(7):719–30. [Accessed 21 July 2017].
  138. Buchheit T, Van de Ven T, Shaw A. Epigenetics and the transition from acute to chronic pain. Pain Med 2012;13(11):1474–90. [Accessed 21 July 2017].
  139. Mauck M, Van de Ven T, Shaw AD. Epigenetics of chronic pain after thoracic surgery. Curr Opin Anaesthesiol 2014;27(1):1–5. [Accessed 21 July 2017].
  140. Wesselmann U, Baranowski AP, Borjesson M, et al. [Accessed 21 July 2017].
  141. Emerging therapies and novel approaches to visceral pain. Drug Discov Today Ther Strateg 2009;6(3):89–95. [Accessed 21 July 2017].
  142. Olesen AE, Farmer AD, Olesen SS, Aziz Q, Drewes AM. Management of chronic visceral pain. Pain Manag 2016;6(5):469–86. [Accessed 21 July 2017].
  143. Queiroz LP. Worldwide epidemiology of fibromyalgia. Curr Pain Headache Rep 2013;17(8):356. [Accessed 21 July 2017].
  144. Hauser W, Zimmer C, Felde E, Kollner V. What are the key symptoms of fibromyalgia? Results of a survey of the German Fibromyalgia Association. Schmerz 2008;22(2):176–83. [Accessed 21 July 2017].
  145. Clauw DJ, Arnold LM, McCarberg BH, FibroCollaborative. The science of fibromyalgia. Mayo Clin Proc 2011;86(9):907–11. [Accessed 21 July 2017].
  146. Macfarlane GJ, Kronisch C, Dean LE, et al. EULAR revised recommendations for the management of fibromyalgia. Ann Rheum Dis 2017;76(2):318–28. [Accessed 21 July 2017].
  147. Angel Garcia D, Martinez Nicolas I, Saturno Hernandez PJ. Clinical approach to fibromyalgia: Synthesis of evidencebased recommendations, a systematic review. Reumatol Clin 2016;12(2):65–71. [Accessed 21 July 2017].
  148. Clauw DJ. Fibromyalgia: A clinical review. JAMA 2014;311(15):1547–55. [Accessed 21 July 2017].
  149. Fitzcharles MA, Ste-Marie PA, Goldenberg DL, et al. 2012 Canadian guidelines for the diagnosis and management of fibromyalgia syndrome: Executive summary. Pain Res Manag 2013;18(3):119–26. [Accessed 21 July 2017].
  150. Hauser W, Thieme K, Turk DC. Guidelines on the management of fibromyalgia syndrome – A systematic review. Eur J Pain 2010;14(1):5–10. [Accessed 21 July 2017].
  151. Goebel A, Barker C, Turner-Stokes L, et al. Complex regional pain syndrome in adults: UK guidelines for diagnosis, referral and management in primary and secondary care. London: RCP, 2012. [Accessed 21 July 2017].
  152. Casale R, Atzeni F, Sarzi-Puttini P. The therapeutic approach to complex regional pain syndrome: Light and shade. Clin Exp Rheumatol 2015;33(1 Suppl 88):S126–39. [Accessed 21 July 2017].
  153. Birklein F, O’Neill D, Schlereth T. Complex regional pain syndrome: An optimistic perspective. Neurology 2015;84(1):89–96. [Accessed 21 July 2017].
  154. Borchers AT, Gershwin ME. Complex regional pain syndrome: A comprehensive and critical review. Autoimmun Rev 2014;13(3):242–65. [Accessed 21 July 2017].
  155. Lohnberg JA, Altmaier EM. A review of psychosocial factors in complex regional pain syndrome. J Clin Psychol Med Settings 2013;20(2):247–54. [Accessed 21 July 2017].
  156. Cossins L, Okell RW, Cameron H, Simpson B, Poole HM, Goebel A. Treatment of complex regional pain syndrome in adults: A systematic review of randomized controlled trials published from June 2000 to February 2012. Eur J Pain 2013;17(2):158–73. [Accessed 21 July 2017].
  157. Goh EL, Chidambaram S, Ma D. Complex regional pain syndrome: A recent update. Burns Trauma 2017;5:2. [Accessed 21 July 2017].
  158. Larochelle MR, Liebschutz JM, Zhang F, Ross-Degnan D, Wharam JF. Opioid prescribing after nonfatal overdose and association with repeated overdose: A cohort study. Ann Intern Med 2016;164(1):1–9. [Accessed 21 July 2017].
  159. Zanini C, Sarzi-Puttini P, Atzeni F, Di Franco M, Rubinelli S. Building bridges between doctors and patients: The design and pilot evaluation of a training session in argumentation for chronic pain experts. BMC Med Educ 2015;15:89. [Accessed 21 July 2017].
  160. Gammaitoni AR, Fine P, Alvarez N, McPherson ML, Bergmark S. Clinical application of opioid equianalgesic data. Clin J Pain 2003;19(5):286–97. [Accessed 21 July 2017].
  161. NSW Therapeutic Advisory Group Inc. Preventing and managing problems with opioid prescribing for chronic noncancer pain. Sydney: NSW TAG, 2015. Available at www. practical-guidance/pain-guidance-july-2015.pdf [Accessed 26 July 2017].
  162. Busse JW, Craigie S, Juurlink DN, et al. Guideline for opioid therapy and chronic noncancer pain. CMAJ 2017;189(18):E659–E66. [Accessed 26 July 2017].
  163. Windmill J, Fisher E, Eccleston C, et al. Interventions for the reduction of prescribed opioid use in chronic non-cancer pain. Cochrane Database Syst Rev 2013(9):CD010323. [Accessed 26 July 2017].
  164. Nilsen HK, Stiles TC, Landro NI, Fors EA, Kaasa S, Borchgrevink PC. Patients with problematic opioid use can be weaned from codeine without pain escalation. Acta Anaesthesiol Scand 2010;54(5):571–79. [Accessed 26 July 2017].
  165. Baron MJ, McDonald PW. Significant pain reduction in chronic pain patients after detoxification from high-dose opioids. J Opioid Manag 2006;2(5):277–82. [Accessed 26 July 2017].
  166. Crisostomo RA, Schmidt JE, Hooten WM, Kerkvliet JL, Townsend CO, Bruce BK. Withdrawal of analgesic medication for chronic low-back pain patients: Improvement in outcomes of multidisciplinary rehabilitation regardless of surgical history. Am J Phys Med Rehabil 2008;87(7):527–36. [Accessed 26 July 2017].
  167. Younger J, Barelka P, Carroll I, et al. Reduced cold pain tolerance in chronic pain patients following opioid detoxification. Pain Med 2008;9(8):1158–63. [Accessed 26 July 2017].
  168. Hooten WM, Mantilla CB, Sandroni P, Townsend CO. Associations between heat pain perception and opioid dose among patients with chronic pain undergoing opioid tapering. Pain Med 2010;11(11):1587–98. [Accessed 26 July 2017].
  169. Wang H, Akbar M, Weinsheimer N, Gantz S, Schiltenwolf M. Longitudinal observation of changes in pain sensitivity during opioid tapering in patients with chronic low-back pain. Pain Med 2011;12(12):1720–26. [Accessed 26 July 2017].
  170. Berna C, Kulich RJ, Rathmell JP. Tapering long-term opioid therapy in chronic noncancer pain: Evidence and recommendations for everyday practice. Mayo Clin Proc 2015;90(6):828–42. [Accessed 26 July 2017].
  171. International Association for the Study of Pain. Classification of chronic pain. 2nd edn. Washington DC: IASP, 2011 aspx?ItemNumber=1673 [Accessed 26 July 2017].
  172. Katz J, Weinrib A, Fashler SR, et al. The Toronto General Hospital Transitional Pain Service: Development and implementation of a multidisciplinary program to prevent chronic postsurgical pain. J Pain Res 2015;8:695–702. [Accessed 26 July 2017].
  173. Denk F, McMahon SB, Tracey I. Pain vulnerability: A neurobiological perspective. Nat Neurosci 2014;17(2):192– 200. [Accessed 26 July 2017].
  174. Eisenberger NI. The neural bases of social pain: Evidence for shared representations with physical pain. Psychosom Med 2012;74(2):126–35. [Accessed 26 July 2017].
  175. Kosek E, Cohen M, Baron R, et al. Do we need a third mechanistic descriptor for chronic pain states? Pain 2016;157:1382–86. [Accessed 26 July 2017].
  176. Merskey H, Bogduk N. International Association for the Study of Pain Task Force on Taxonomy. Classification of chronic pain: Descriptions of chronic pain syndromes and definitions of pain terms. 2nd edn. Seattle: IASP Press, 1994; p. 222. [Accessed 26 July 2017].
  177. Smart KM, Blake C, Staines A, Thacker M, Doody C. Mechanisms-based classifications of musculoskeletal pain: Part 3 of 3: Symptoms and signs of nociceptive pain in patients with low back (+/– leg) pain. Man Ther 2012;17(4):352–57. [Accessed 26 July 2017].
  178. Costigan M, Scholz J, Woolf CJ. Neuropathic pain: A maladaptive response of the nervous system to damage. Annu Rev Neurosci 2009;32:1–32. [Accessed 26 July 2017].
  179. Freynhagen R, Baron R, Gockel U, Tolle TR. painDETECT: A new screening questionnaire to identify neuropathic components in patients with back pain. Curr Med Res Opin 2006;22(10):1911–20. [Accessed 26 July 2017].
  180. O’Connor AB, Dworkin RH. Treatment of neuropathic pain: An overview of recent guidelines. Am J Med 2009;122(10 Suppl):S22–32. [Accessed 26 July 2017].
  181. Arendt-Nielsen L, Nie H, Laursen MB, et al. Sensitization in patients with painful knee osteoarthritis. Pain 2010; 149(3):573–81. [Accessed 26 July 2017].
  182. Kosek E, Ordeberg G. Lack of pressure pain modulation by heterotopic noxious conditioning stimulation in patients with painful osteoarthritis before, but not following, surgical pain relief. Pain 2000;88(1):69–78. [Accessed 26 July 2017].
  183. Aranda-Villalobos P, Fernandez-de-Las-Penas C, NavarroEspigares JL, et al. Normalization of widespread pressure pain hypersensitivity after total hip replacement in patients with hip osteoarthritis is associated with clinical and functional improvements. Arthritis Rheum 2013;65(5):1262–70. [Accessed 26 July 2017].
  184. Graven-Nielsen T, Wodehouse T, Langford RM, ArendtNielsen L, Kidd BL. Normalization of widespread hyperesthesia and facilitated spatial summation of deep-tissue pain in knee osteoarthritis patients after knee replacement. Arthritis Rheum 2012;64(9):2907–16. [Accessed 26 July 2017].
  185. Kosek E, Ordeberg G. Abnormalities of somatosensory perception in patients with painful osteoarthritis normalize following successful treatment. Eur J Pain 2000;4(3):229–38. [Accessed 26 July 2017].
  186. Rosenquist EWK. Evaluation of chronic pain in adults. UpToDate 2016 evaluation-of-chronic-pain-in-adults?source=search_ result&search=pain%20assessment&selectedTitle=1~150 - H15544430 [Accessed 3 March 2017].
  187. Kirsh KL, Jass C, Bennett DS, Hagen JE, Passik SD. Initial development of a survey tool to detect issues of chemical coping in chronic pain patients. Palliat Support Care 2007;5(3):219–26. [Accessed 3 March 2017].
  188. Flor H. Psychological pain interventions and neurophysiology: Implications for a mechanism-based approach. Am Psychol 2014;69(2):188–96. [Accessed 3 March 2017].
  189. Nicholas MK, Linton SJ, Watson PJ, Main CJ, Decade of the Flags Working Group. Early identification and management of psychological risk factors (‘yellow flags’) in patients with low back pain: A reappraisal. Phys Ther 2011;91(5):737–53. [Accessed 3 March 2017].
  190. Ip HY, Abrishami A, Peng PW, Wong J, Chung F. Predictors of postoperative pain and analgesic consumption: A qualitative systematic review. Anesthesiology 2009;111(3):657–77. [Accessed 3 March 2017].
  191. Leeuw M, Goossens ME, Linton SJ, Crombez G, Boersma K, Vlaeyen JW. The fear-avoidance model of musculoskeletal pain: Current state of scientific evidence. J Behav Med 2007;30(1):77–94. [Accessed 3 March 2017].
  192. Hjermstad MJ, Fayers PM, Haugen DF, et al. Studies comparing numerical rating scales, verbal rating scales, and visual analogue scales for assessment of pain intensity in adults: A systematic literature review. J Pain Symptom Manage 2011;41(6):1073–93. [Accessed 3 March 2017].
  193. Chen L, Vo T, Seefeld L, et al. Lack of correlation between opioid dose adjustment and pain score change in a group of chronic pain patients. J Pain 2013;14(4):384–92. [Accessed 3 March 2017].
  194. Chou R, Turner JA, Devine EB, et al. The effectiveness and risks of long-term opioid therapy for chronic pain: A systematic review for a National Institutes of Health Pathways to Prevention Workshop. Ann Intern Med 2015;162(4):276–86. [Accessed 3 March 2017].
  195. Sehgal N, Manchikanti L, Smith HS. Prescription opioid abuse in chronic pain: A review of opioid abuse predictors and strategies to curb opioid abuse. Pain Physician 2012;15(3 Suppl):ES67–92. [Accessed 3 March 2017].
  196. Gordon A, Cone EJ, DePriest AZ, Axford-Gatley RA, Passik SD. Prescribing opioids for chronic noncancer pain in primary care: Risk assessment. Postgrad Med 2014;126(5):159–66. [Accessed 3 March 2017].
  197. Di Blasi Z, Harkness E, Ernst E, Georgiou A, Kleijnen J. Influence of context effects [Accessed 3 March 2017].
This event attracts CPD points and can be self recorded

Did you know you can now log your CPD with a click of a button?

Create Quick log

Advertising